HCN Oncology Essentials: Treating Breast Cancer | Managing Transplant-Ineligible Patients| NETosis | ASCO CRC HighlightsOctober 12, 2021 | Oncology Obstetrics & Gynecology Looking for the Optimal Endocrine Partner for ER+, HR+, ERBB2- Advanced Breast Cancer A phase 2 clinical trial involving 486 patients examined whether fulvestrant or letrozole is more effective in treating advanced breast cancer. The results, published in JAMA Oncology, confirmed that letrozole is the preferred treatment in patients with advanced forms of breast cancer. Although fulvestrant demonstrated significant antitumor activity, it did not significantly impact the overall survival rate of breast cancer patients when compared to letrozole. Read full article Hematology Your Approach to Treating this Transplant-Ineligible Patient with Ph+ ALL? In ASH Clinical News, Dr. Geoffrey Uy, a professor in the Oncology Division at Washington University School of Medicine in St. Louis, discusses treatment options for a transplant-ineligible patient who has Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL). The patient under review is a 61-year-old female diagnosed with Ph+ ALL who has multiple comorbidities and is not a candidate for allogeneic hematopoietic cell transplantation. Read full article Hematology More Insight into the Role of NETosis in Thrombotic Events in Myeloproliferative Neoplasms A study published in Blood Advances finds that higher levels of NETosis in myeloproliferative neoplasms (MPNs) are not linked to thrombotic events. The study determined that while NETosis may play a role in facilitating thrombosis, it is not a sole causative determinant in MPN-associated thrombophilia. Read full article Gastroenterology CRC: Collected Highlights with Commentary from ASCO 2021 At this year’s ASCO annual meeting, CRC management insights were revealed in several abstract presentations covering pembrolizumab, regorafenib, immunotherapies, trifluridine/tipiracil plus bevacizumab, and an antibody-drug conjugate targeting HER2. Read full article
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH